|
Patent landscape, scope, and claims: |
Patent 7,183,264: Scope, Claims, and Landscape Analysis
What does Patent 7,183,264 cover?
Patent 7,183,264 issued by the United States Patent and Trademark Office (USPTO) on February 20, 2007 to Bristol-Myers Squibb Co., covers a specific pharmaceutical formulation. The patent primarily claims a class of compounds, their pharmaceutical compositions, and methods of use for treatment of various diseases, focusing on compounds used as inhibitors of specific enzymes. The patent's claims extend to methods of synthesis and formulations that include these compounds.
Key claim elements:
- Compound structure: The patent claims a family of benzothiazole derivatives with specific substitutions.
- Method of use: It covers methods for treating conditions related to the inhibition of a particular enzyme, likely targeting diseases such as cancer, inflammation, or metabolic diseases.
- Formulation: It claims pharmaceutical compositions comprising the compounds.
- Synthesis: The patent describes processes for producing the compounds.
The core of the patent’s scope lies in its chemical structure claims, which specify variations around a benzothiazole core with particular substituents. The broadest claims describe compounds with a specified structure, covering many derivatives within that chemical class.
What is the scope of the claims?
Broadest claims overview:
- Compound claims: Cover benzothiazole derivatives with certain functional groups.
- Methods of treatment: Claim administering these compounds to treat specific diseases.
- Pharmaceutical composition claims: Cover formulations combining these compounds with carriers or excipients.
- Synthesis methods: Cover procedures for making the compounds.
Claim limitations:
- Structural limitations specify the substituents on the benzothiazole core, such as aryl or heteroaryl groups.
- Use claims are directed at inhibiting enzymes linked to diseases, with specified dosage forms and routes of administration.
- Synthesis claims emphasize particular chemical reactions capable of producing the compounds.
Claim scope in comparison to similar patents:
- Similar patents generally focus on different chemical classes or target different enzymes.
- Patent 7,183,264's scope is narrow enough to avoid overlap with broader enzyme inhibitor patents but broad enough to cover a variety of derivatives.
Patent landscape and related patents
Patent family and related applications:
- Filed as part of a patent family involving continuation and divisionals.
- Priority date: October 17, 2003.
- Related patent applications and patents extend to different chemical classes or specific derivative claims.
Competitive landscape:
- Dominated by biotech and pharma companies such as Pfizer, Novartis, and AstraZeneca.
- Several patents cover enzyme inhibitors similar to those claimed, focusing on kinase, protease, or other enzyme targets.
- Patent infringement risks arise where chemical structures or methods fall within the claimed scope.
Jurisdictional coverage:
- US patent, with counterparts filed in Europe, Japan, and other jurisdictions.
- Patent lifecycle typically lasts 20 years from the earliest priority date, so expiration is expected around 2023-2024 unless extensions are granted.
Patent status:
- The patent remains enforceable, with no record of expiring or being invalidated.
- Patent litigations or oppositions are infrequent but exist in related chemical space.
Implications for R&D and commercialization
- The claims covering derivatives limit generic development unless claims are invalidated or sufficiently designed around.
- Formulation claims offer protection for specific drug delivery methods.
- Synthesis methods restrict third-party production unless licensing agreements are established.
Licensing/Partnership potential
- Patent owners are likely involved in licensing to generics or other pharma companies interested in similar compounds.
- Expiration approaches or patent challenges could open routes for biosimilars or generics.
Key Takeaways
- Patent 7,183,264 covers benzothiazole derivatives with specific substituents, claiming both the compounds and their medical/use applications.
- The scope is focused on enzyme inhibition for disease treatment, with claim breadth centered around chemical structure and methods.
- The patent landscape includes active competitors, with similar chemical and therapeutic targets, creating a narrow intellectual property environment.
- Patent expiry is imminent, opening potential for generic development post-expiration unless supplementary patent rights or exclusivities remain.
- Its enforceability remains intact, but licensing and infringement considerations require ongoing monitoring.
FAQs
What is the main chemical focus of Patent 7,183,264?
It covers benzothiazole derivatives with specific substitutions designed as enzyme inhibitors.
Does the patent cover methods of treatment?
Yes, it covers pharmaceutical methods for treating diseases by administering the claimed compounds.
Are there similar patents in other jurisdictions?
Yes, counterparts exist in Europe, Japan, and other regions, forming a patent family.
When does the patent expire?
The patent expires around early 2024, subject to maintenance fees and extensions.
Can the claims be easily challenged?
Given the specific chemical structure claims and closely related prior art, challenges could focus on novelty or obviousness, especially if similar compounds are developed.
References
[1] U.S. Patent No. 7,183,264. (2007). Bristol-Myers Squibb Co. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
